Skip to main content

Table 3 Clinical Response

From: Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Characteristic All evaluable patients (n = 24)
Best radiographic response  
 Complete response (CR), no. (%) 0 (0)
 Partial response (PR), no. (%) 2 (8)
 Stable disease (SD), no. (%) 5 (21)
 Progressive disease (PD), no. (%) 17 (71)
Median PFS, days (range) 42 (7–282)
Median OS, days (range) 121 (15–415)